- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02671058
Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
Randomized, Open Label, Crossover Study Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Administered as a Suppository With the Sephure® Rectal Suppository Applicator Compared With Cortenema in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male and female subjects between 18 to 45 years of age, inclusive, at the time of Screening.
Female subjects must be:
Of non childbearing potential (surgically sterile [hysterectomy, oophorectomy or bilateral tubal ligation] or post-menopausal >1 year with follicle stimulating hormone [FSH] > 40 U/L), or Non pregnant, non lactating females of childbearing potential who are able and willing to undertake adequate measures to prevent a pregnancy including the use of any medically acceptable forms of birth control by the subject or partner (hormonal birth control, abstinence, diaphragm with spermicide, condom with spermicide, intrauterine device, vasectomy or surgical sterilization) from Screening until the End of Study.
- Male subjects must be able and willing to undertake adequate measures to prevent a pregnancy throughout the study including the use of any medically acceptable forms of birth control by the subject or partner (hormonal birth control, abstinence, diaphragm with spermicide, condom with spermicide, intrauterine device, vasectomy, surgical sterilization or post menopausal partner) from Screening until the End of Study.
- Body mass index (BMI) of ≥ 18.0 and ≤ 30.0 kg/m2 at the time of Screening.
- Subject is willing and able to provide informed consent.
- Subject is willing and able to be confined to the CRU and adhere to the study and lifestyle restrictions.
Exclusion Criteria:
- History of clinically significant illness or surgery as determined by the Principal Investigator or designee, within 5 years prior to the first IMP administration.
- History or evidence of any clinically significant pathology including neurological, cardiovascular, endocrine, pulmonary, gastrointestinal, renal, hepatic, hematological, immunological, psychiatric or metabolic disorder(s) as determined by the Principal Investigator or designee.
- Any significant rectal pathology that, in the opinion of the Principal Investigator or designee, would be a contraindication (or warning) with a hydrocortisone acetate suppository or hydrocortisone retention enema including rectal obstruction, abscess, perforation, active fungal infection(s) and/or bacterial infection(s).
- Subject has had anal sex, cosmetic anal bleaching or perianal waxing within 30 days prior to the first IMP administration.
- History of constipation, diarrhea or frequent bowel movements per day within 30 days prior to the first IMP administration.
- Any clinically significant abnormality (including clinically significant laboratory test result[s]) found at Screening or febrile illness or infection within 7 days prior to Screening through Admission (Day 1 of Treatment Period 1) to the CRU.
- Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti HCV), or human immunodeficiency virus (HIV) antibody at Screening.
- Clinically significant electrocardiogram (ECG) abnormality at Screening, as determined by the Principal Investigator or designee.
- Positive pregnancy test (females only) at Screening or Admission (Day 1 of Treatment Periods 1 or 2) to the CRU.
- Subject has history of alcohol abuse or of significant regular alcohol use within 1 year prior to Screening, defined as exceeding 14 units of alcohol per week, where, 1 unit = 12 ounces of beer, 5 ounces of wine or 1.5 ounces of hard liquor.
- Positive serum alcohol test at Screening or Admission (Day 1 of Treatment Periods 1 or 2) to the CRU.
- History of regular tobacco use or use of nicotine containing products to control tobacco use within the past 6 months prior to Screening.
- Positive urine drug test (including amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates and phencyclidine) at Screening or Admission (Day 1 of Treatment Periods 1 or 2) to the CRU.
- Use of over the counter (OTC) medications (including oral natural health products, vitamin and herbal supplements) within 7 days prior to the first IMP administration until the End of Study or use of prescription medication within 14 days prior to the first IMP administration until the End of Study. By exception, acetaminophen <1000 mg per day, hormonal contraception and hormonal replacement therapy are permitted.
- Known allergy or history of hypersensitivity to hydrocortisone or any of the inert components of either of the formulations being tested.
- Participation in another clinical study within 60 days prior to the first IMP administration. Participation is considered the last dose of IMP from another study.
- Donation or loss of blood (> 100 mL) of either whole blood or plasma within 60 days prior to the first IMP administration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cortenema
Hydrocortisone retention enema (Cortenema) administered rectally as a single dose; each dose unit delivers 100 mg of hydrocortisone per 60 mL.
|
Hydrocortisone Administered as a Liquid Enema
|
Experimental: Hydrocortisone acetate
Hydrocortisone acetate suppository 90 mg administered rectally as a single dose with the Sephure Rectal Suppository Applicator
|
Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
primary PK endpoints
Time Frame: at time 0,1, 2 and 24 hours
|
Maximum plasma concentration
|
at time 0,1, 2 and 24 hours
|
primary PK endpoints
Time Frame: at time 0,1, 2 and 24 hours
|
Area under the concentration-time curve
|
at time 0,1, 2 and 24 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Marck C Ensign, Executive VP Product Development
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CINC-2015-BA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Cortenema
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedAdvanced Malignant Neoplasm | Dermatologic ComplicationUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Completed
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)TerminatedProstate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Cancer | Stage IV Prostate CancerUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic SyndromeUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.Active, not recruitingDiffuse Large B-Cell Lymphoma | Plasmablastic Lymphoma | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Adult Burkitt Lymphoma | MYC Gene MutationUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid LeukemiaUnited States, Canada, Puerto Rico, Australia
-
National Cancer Institute (NCI)Active, not recruitingRecurrent B Acute Lymphoblastic LeukemiaUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Childhood T Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand
-
National Cancer Institute (NCI)Not yet recruitingB Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage
-
Children's Oncology GroupNational Cancer Institute (NCI); EsPhALL Network/ BFM Study GroupRecruitingAcute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute LeukemiaUnited States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel